[A23-36] Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2023
Project no.:
A23-36
Commission:
Commission awarded on 24.04.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-97 | Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-98 | Cemiplimab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-60 | Cemiplimab - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-37 | Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V | Commission completed |